Compare VanEck Junior Gold Miners (GDXJ) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Junior Gold Miners vs Pfizer Inc — how do they compare? VanEck Junior Gold Miners trades at $114.32 (market cap $8.22B), while Pfizer Inc trades at $28.21 (market cap $158.56B). The key difference: Pfizer Inc is far larger — about 19.3× VanEck Junior Gold Miners's market cap, and Pfizer Inc pays a 6.18% dividend while VanEck Junior Gold Miners pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Junior Gold Miners for 41 Days and Pfizer Inc for 158 Days on average.
| GDXJ | PFE | |
|---|---|---|
Market Cap | $8.22B | $158.56B |
Volume | 3,212,198 | 44,138,282 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $156.19 | $29.02 |
52-Week Low | $87.56 | $23.67 |
Typical Hold Time | 41 Days | 158 Days |
Enterprise Value | — | $210.06B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GDXJ, the VanEck Junior Gold Miners ETF, trades at $114.39, up 4.81% in the last 24 hours. The technical outlook is bearish, with moving averages and key indicators like ADX signaling selling pressure. Recent news highlights multiple junior gold mining companies being added to the ETF's underlying index, potentially increasing its diversification and appeal. However, key financial ratios such as P/E and P/S are unavailable for direct analysis of the ETF's valuation.
The outlook for GDXJ is mixed, balancing recent index additions against a bearish technical backdrop. Investment opportunities lie in exposure to junior gold miners amid high gold prices, but risks include sector volatility and the ETF's current negative momentum. Investors should weigh the potential for broader market recognition against prevailing selling pressure.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Junior Gold Miners
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
